Best drug dosing software for obese patients: weight-based dosing tools compared

Every drug reference on the market will give you a milligram-per-kilogram dose. Almost none of them will tell you which kilograms. That gap is where weight-based dosing in obesity actually lives, and it is the thing to evaluate before signing a subscription, because a reference that publishes a dose without publishing a weight basis has handed the hard half of the decision back to you.

This is a comparison of what US clinicians can buy for this problem, what each option is verified to cost, and the one question that separates a tool that helps from a tool that looks like it helps. Every price here was checked at the vendor's own material in August 2026. Where a vendor publishes nothing, this guide says so rather than repeating a figure from a review site.

Why obesity breaks the arithmetic

Most milligram-per-kilogram labeling was written against actual body weight, and it works until adipose tissue becomes a large share of that weight. Hydrophilic drugs stay largely in lean tissue and extracellular water, so dosing them on a scale weight that is substantially fat produces a larger dose than the patient's pharmacokinetics call for. Lipophilic drugs distribute differently. There is no single rule, which is exactly the problem: the correct weight basis is a property of the drug, not of the patient.

The profession solved this with conventions rather than with data. Ideal body weight by the Devine equation is a height-derived stand-in for lean mass, and it entered practice through gentamicin dosing in obese patients rather than through any statement about healthy weight. Adjusted body weight, ideal weight plus 0.4 of the gap between actual and ideal, is the usual middle position. If you want the equations side by side with the arithmetic visible, the ideal body weight calculator runs Devine, Robinson, Miller and Hamwi against the same patient and shows how far apart they land.

What makes this a purchasing question rather than a training question is that the reference sitting on the pharmacist's screen is where the convention gets applied or skipped. Enoxaparin is the case that shows how little help the labeling gives: the prescribing information states that the safety and efficacy of prophylactic doses in patients with a body mass index above 30 has not been fully determined and that there is no consensus for dose adjustment, and notes that after repeated subcutaneous 1.5 mg/kg once-daily dosing the mean AUC of anti-Factor Xa activity is marginally higher at steady state in obese healthy volunteers than in non-obese controls. That is an honest label. It is also an explicit handoff to institutional protocol, and your software either supports that protocol or it does not.

The options, and what they are verified to cost

The pattern in that table is worth naming, because it repeats across this whole category. The vendors that publish a price are the ones selling to an individual. The vendors that publish nothing are the ones selling to a purchasing committee. Transparency here tracks who signs the check, not product quality, and it means the two products most likely to end up as your department standard are the two you cannot price without a sales call.

It also means the free options deserve a fairer hearing than they usually get. ClinCalc shows its working, which for a weight-based dosing question is the single most useful property a tool can have, and its author has stated the site will stay free. The catch is structural rather than technical: it is maintained by an individual pharmacist author, so there is no vendor contract, no support path and no service commitment. A department that quietly makes a free website its standard has taken on an availability risk it has not written down anywhere, and the usual mitigation is to keep the endpoint under continuous availability checks so the failure is discovered before a pharmacist meets it mid-shift rather than after.

Which drug reference is best for dosing in obese patients?

There is no single best, and any guide that names one is selling something. For depth of drug-specific monograph content at a visible price, Lexidrug at $29.99 per month is the strongest individual purchase in this list. For a health system that needs one contracted reference the whole institution cites, Micromedex or UpToDate is the realistic shortlist, and both require a quote. For the arithmetic itself, a free calculator that shows its working beats a paid one that does not, because in obesity the value is in seeing which weight went in.

Do you use actual or ideal body weight for drug dosing?

It depends on the drug, and that is not a hedge. Actual body weight is correct for most labeling and for any patient at or below their ideal weight. Ideal body weight is used where the dose should track lean mass. Adjusted body weight, ideal plus 0.4 of the excess, is the convention in obesity when neither of the other two fits. The decision belongs to the drug and your institutional protocol, so the practical requirement for software is that it lets you state the basis explicitly instead of silently assuming one.

What is adjusted body weight used for?

It is used when a patient sits well above their ideal weight and the drug is dosed on a lean-mass proxy. Many protocols set the trigger at actual weight exceeding ideal weight by 20 to 30 percent. Below that the adjusted and actual figures converge and the extra step changes nothing. The 0.4 correction factor is the usual convention rather than a physiological constant, and specific protocols use 0.3 or 0.5 without either being wrong.

Does vancomycin get dosed on actual or adjusted body weight?

Vancomycin is the case where the profession largely stopped arguing about weight conventions. The 2020 ASHP, IDSA, PIDS and SIDP consensus guideline moved monitoring to an AUC target of 400 to 600 and away from trough-only targets, which means the initial weight-based estimate matters less once measured concentrations arrive. Get the first dose from your protocol, then let two timed levels replace the assumption. The vancomycin AUC calculator runs that two-level arithmetic, and the buyer's comparison of vancomycin dosing software covers when a Bayesian platform is worth a purchase order.

Does obesity change renal dosing thresholds?

Not the thresholds, but very much the estimate you compare against them. The weight basis is an input to Cockcroft-Gault before it is an input to anything else, so switching a 118 kg patient between actual, ideal and adjusted weight can move the clearance estimate across a labeled band and change the recommended interval. Reported eGFR carries a second version of the same trap, because it is indexed to a body surface area of 1.73 square metres and has to be de-indexed before it is compared with a threshold stated in mL per minute. The creatinine clearance calculator makes the weight basis an explicit selection for that reason.

What to actually test during the trial

Feature lists will not separate these products, because they all list drug monographs and they all list dosing. Four questions will.

First, can you state the weight basis? Take a real 118 kg patient at 70 inches and try to dose a renally cleared drug. If the tool accepts a weight without ever asking or showing which basis it assumed, you are trusting a default you cannot see. Second, does it show the arithmetic? A clearance figure with no visible inputs cannot be checked by the pharmacist who recalculates it at 3am, and reproducibility between clinicians is worth more here than a marginally better point estimate.

Third, what happens at the edges? Try a patient below ideal body weight, and try one with an amputation. The second is the honest stress test, because it forces the tool to admit whether it has any concept of a segment adjustment or is simply running height through an equation. Fourth, who answers the phone? For a free tool the answer is nobody, which may be fine, but it should be a decision rather than a discovery.

Run those four on a two-week trial and the shortlist usually collapses to one. Pricing the result across a department is a separate exercise, and the institutional license guide covers what changes when a per-seat rate becomes a contract.

Where this leaves the decision

Buy for the workflow you actually have. A single pharmacist doing weight-based dosing a few times a shift is well served by a visible-arithmetic calculator and a $29.99 monthly monograph subscription, and does not need a purchasing committee. A health system standardizing across departments is buying contractual certainty, integration and a support path, and should expect no published price for it.

What neither purchase settles is the rest of the medication list. A dose calculated on the right weight basis still has to survive the interaction, the contraindication and the renal adjustment sitting further down the chart, and those checks belong beside the arithmetic rather than after it. That is the case for treating dosing weight as one line of a prescribing check rather than as a standalone lookup.